Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

From Hemodynamics to Starling Curves: Applications of Energetic Analysis in Heart Failure Patients.

JACC. Heart failure·2026
Same author

Eisenmenger Syndrome Complicated by Hemorrhagic Hereditary Telangiectasia: Unique Intersection of Hemorrhage, Cyanosis, and Thrombosis.

JACC. Case reports·2026
Same author

Aortic insufficiency and right heart failure in patients treated with durable left ventricular assist devices after preoperative support with microaxial flow devices.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2026
Same author

The Diastolic Dominance Index: A Bedside Doppler Tool for Aortic Insufficiency in Continuous-Flow Left Ventricular Assist Devices.

ASAIO journal (American Society for Artificial Internal Organs : 1992)·2026
Same author

Baroreflex Activation Therapy Invasive Hemodynamic "Reverse Ramp" Titration.

Journal of the Society for Cardiovascular Angiography & Interventions·2026
Same author

Resiliency of the right ventricle and long-term outcomes in LVAD recipients bridged with temporary mechanical support.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2026
Same journal

Predictors and Outcomes of Heart Failure Diagnosis in the Community When Compared to Acute Care Settings: Insights from Linked Administrative Health Databases.

Journal of cardiac failure·2026
Same journal

Digitalis Today: From Doctrine to Disrepute to Disciplined Reconsideration.

Journal of cardiac failure·2026
Same journal

What Are HFpEF Mimics and What Are They Mimicking? Insights Into Our Conceptualization of Heart Failure With Preserved Ejection Fraction as a Disease.

Journal of cardiac failure·2026
Same journal

Right Ventricular Function and Echocardiographic Characteristics After Left Atrial to Coronary Sinus Shunting; Insights from ALT-FLOW Early Feasibility Study 3 Year Follow-Up.

Journal of cardiac failure·2026
Same journal

Greater Splanchnic Nerve Ablation Produces Echocardiographic Evidence of Reduced Left Ventricular Filling Pressures Across 12 Months of Follow-Up.

Journal of cardiac failure·2026
Same journal

JCF In Case You Missed It! Summary of American College of Cardiology (ACC) 2026.

Journal of cardiac failure·2026
See all related articles

Related Experiment Video

Updated: May 27, 2025

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device
07:41

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device

Published on: July 20, 2022

1.8K

Mitigating Post-operative Right Ventricular Dysfunction After Left Ventricular Assist Device: The RV Protection

Anthony J Kanelidis1, Leo Gozdecki1, Mark N Belkin1

  • 1Department of Medicine, Section of Cardiology, Advanced Heart Failure and Transplant Cardiology, University of Chicago Medical Center, Chicago, IL.

Journal of Cardiac Failure
|February 15, 2025
PubMed
Summary
This summary is machine-generated.

A new strategy to protect the right ventricle (RV) after left ventricular assist device (LVAD) implantation significantly improved survival rates, reducing hemodynamic-related adverse events (HDREs) and hemocompatibility-related adverse events (HRAEs). This approach offers better outcomes for LVAD patients.

Keywords:
Left ventricular assist devicehemocompatibility-related adverse eventshemodynamic-related eventsright ventricular failure

More Related Videos

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

3.5K
Implantation of the Syncardia Total Artificial Heart
16:11

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

35.1K

Related Experiment Videos

Last Updated: May 27, 2025

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device
07:41

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device

Published on: July 20, 2022

1.8K
Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

3.5K
Implantation of the Syncardia Total Artificial Heart
16:11

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

35.1K

Area of Science:

  • Cardiovascular Surgery
  • Mechanical Circulatory Support
  • Heart Failure Management

Background:

  • Left ventricular assist devices (LVADs) improve outcomes but hemodynamic-related adverse events (HDREs), like right ventricular failure (RVF), persist.
  • HeartMate 3 LVAD has improved hemocompatibility, yet HDREs remain a significant challenge.
  • Investigating strategies to mitigate RVF and other HDREs post-LVAD is crucial.

Purpose of the Study:

  • To evaluate a comprehensive, upfront RV protection strategy to reduce RVF and other HDREs after LVAD implantation.
  • To compare the efficacy of this novel RV protection strategy against usual care.
  • To assess the impact on survival free from HDREs and HRAEs.

Main Methods:

  • Prospective randomized trial comparing RV-protection strategy with usual care in LVAD patients.
  • RV-protection strategy involved hemodynamic, ventilatory, and pharmaceutical optimization targeting RV afterload, preload, perfusion, contractility, rate/rhythm, and geometry.
  • Primary outcome: survival free from HDREs or HRAEs at 24 weeks; secondary outcomes: severe RVF.

Main Results:

  • The RV-protection strategy group showed significantly higher survival rates free from HDREs or HRAEs at 24 weeks (80% vs 40%, P=0.04).
  • No HDREs occurred in the RV-protection strategy group compared to 30% in the usual care group (P=0.067).
  • Severe RVF was not observed in the RV-protection strategy group versus 30% in the usual care group (P=0.20).

Conclusions:

  • A comprehensive, upfront RV protection strategy significantly enhances survival free from HDREs and HRAEs post-LVAD implantation.
  • This strategy effectively mitigates the risk of RVF and other HDREs.
  • The findings support the adoption of this proactive RV protection protocol in LVAD management.